Tag: hereditary angioedema therapeutics market outlook

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Hereditary Angioedema Therapeutics Market Forecast: Value Set To Climb From $9.27 Billion To $19.03 Billion

The hereditary angioedema therapeutics market size has expanded considerably in recent years. This market is set to expand from $7.77 billion in 2025 to $9.27 billion in 2026, showing a compound annual growth rate (CAGR) of 19.3%. The factors contributing to its historical growth include limited awareness about hae, a dependence on hospital-based therapy, fewer approved therapeutic options available, a reliance on intravenous administration methods, and low prevalence diagnosis rates.

The hereditary angioedema therapeutics market is anticipated to experience substantial expansion in the coming years. Its valuation is projected to reach $19.03 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 19.7%. This expansion during the forecast period can be linked to several factors, including the increasing development of recombinant C1 esterase inhibitors, the uptake of subcutaneous delivery methods, a rise in the use of prophylactic therapies, the broadening of specialty pharmacy networks, and greater investment in research for rare diseases. Key developments expected within this period involve the evolution of personalized therapies, an increase in orphan drug approvals, ongoing progress in subcutaneous drug delivery systems, the creation of on-demand treatment solutions, and the enlargement of both hospital and retail pharmacy networks.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=81822225&type=smp&name=Hereditary%20Angioedema%20Therapeutics%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Hereditary Angioedema Therapeutics Market Development Factors: What’s Supporting Demand?

The escalating healthcare expenditure is anticipated to drive the expansion of the hereditary angioedema therapeutics market in the coming years. Healthcare expenditure denotes the overall sum of resources, including financial assets, dedicated to healthcare products and services within a specific timeframe and geographical area. Higher healthcare spending enables enhanced investment in research and development initiatives focused on comprehending the fundamental causes of hereditary angioedema and devising innovative treatment solutions. For example, in June 2025, data from the Centers for Medicare & Medicaid Services (CMS), the US federal agency, indicated that National Health Expenditure (NHE) grew 7.5% to $4.9 trillion in 2023, equivalent to $14,570 per person, and comprised 17.6% of Gross Domestic Product (GDP). Hospital expenditures experienced a 10.4% increase to $1,519.7 billion in 2023, surpassing the 3.2% growth recorded in 2022. Therefore, the rise in healthcare expenditure is propelling the growth of the hereditary angioedema therapeutics market.

Hereditary Angioedema Therapeutics Market Segment Breakdown: Which Categories Lead On Revenue?

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-Demand

Hereditary Angioedema Therapeutics Market Transformation Trends: What Innovations Are Driving Change?

Leading companies within the hereditary angioedema (HAE) therapeutics market are engaged in the development of cutting-edge treatments, such as oral plasma kallikrein inhibitors. These innovations aim to optimize patient care and provide effective, immediate solutions for HAE attack relief, thereby enhancing overall patient well-being and life quality. Oral plasma kallikrein inhibitors are orally administered medications designed to suppress the enzyme plasma kallikrein, which assists in managing and reducing the intensity of hereditary angioedema episodes. An example of this progress is KalVista Pharmaceuticals, a US-based biopharmaceutical firm, which in September 2024, obtained a US. Food and Drug Administration New Drug Application for Sebetralstat. This development is intended to offer HAE patients a more user-friendly, non-invasive treatment option, distinct from intravenous or subcutaneous drugs. Such a treatment addresses the increasing need for rapid and efficient oral therapies that can be used immediately upon the onset of a hereditary angioedema attack.

Hereditary Angioedema Therapeutics Market Leading Players And Competitive Positioning

Major companies operating in the hereditary angioedema therapeutics market are Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sobi AB, OctoPharma USA, HAE Pharma, Argenx SE, ImmunoGen Inc., Ionis Pharmaceuticals (for pipeline HAE therapies), PharmAthene Inc., BioMarin Pharmaceutical Inc.

View The Full Hereditary Angioedema Therapeutics Market Report:

https://thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Hereditary Angioedema Therapeutics Market Largest Region: Which Geography Holds The Highest Market Share?

North America was the largest region in the global hereditary angioedema therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Hereditary Angioedema Therapeutics Market Size Forecast: How Large Could The Market Become By 2030?

The market for hereditary angioedema therapeutics has experienced significant expansion in recent years. Projected to rise from $7.77 billion in 2025 to $9.27 billion in 2026, it reflects a compound annual growth rate (CAGR) of 19.3%. This historical growth has been driven by factors such as restricted understanding of HAE, a reliance on hospital-centered treatment, a limited number of authorized therapeutic choices, dependence on intravenous delivery methods, and low rates of diagnosis due to the condition’s rarity.

The market for hereditary angioedema therapeutics is projected to experience significant expansion over the coming years. By 2030, its value is anticipated to reach $19.03 billion, driven by a compound annual growth rate (CAGR) of 19.7%. This forecasted growth is fueled by several factors, including the increasing use of recombinant C1 esterase inhibitors, a shift toward subcutaneous delivery methods, a rise in prophylactic therapy adoption, the growth of specialty pharmacy channels, and heightened investment in rare disease research. Key trends shaping the market during this period involve the development of personalized therapies, a higher number of orphan drug approvals, progress in subcutaneous drug delivery systems, the creation of on-demand treatment options, and the broadening of hospital and retail pharmacy networks.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Hereditary Angioedema Therapeutics Market Growth Drivers And Industry Catalysts

The rising levels of healthcare spending are anticipated to propel the hereditary angioedema therapeutics market forward in the coming years. Healthcare expenditure is defined as the overall volume of resources, including financial funds, allocated to medical goods and services within a defined timeframe in a specific region. As healthcare spending increases, more resources become available for supporting research and development efforts aimed at uncovering the root causes of hereditary angioedema and creating innovative treatments. As an example, data from the Centers for Medicare & Medicaid Services (CMS), a federal agency in the United States, shows that in June 2025, National Health Expenditure (NHE) rose by 7.5% to $4.9 trillion in 2023, equating to $14,570 per person, and representing 17.6% of the Gross Domestic Product (GDP). Additionally, hospital expenditures saw a 10.4% increase, reaching $1,519.7 billion in 2023, which is notably faster than the 3.2% growth observed in 2022. Consequently, this upward trend in healthcare spending is fueling expansion in the hereditary angioedema therapeutics market.

Hereditary Angioedema Therapeutics Market Segment Analysis: What Are The Major Market Categories?

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-Demand

Hereditary Angioedema Therapeutics Market Trends Influencing Long-Term Demand

Key industry participants in the hereditary angioedema (HAE) therapeutics market are actively designing novel therapies, specifically oral plasma kallikrein inhibitors, aimed at improving disease control and delivering effective, on-demand relief from HAE attacks, which ultimately boosts patient outcomes and quality of life. These oral plasma kallikrein inhibitors are administered by mouth and function by suppressing the plasma kallikrein enzyme, reducing the intensity of hereditary angioedema episodes. As an example, in September 2024, KalVista Pharmaceuticals, a biopharmaceutical firm headquartered in the United States, obtained US Food and Drug Administration acceptance of its New Drug Application for Sebetralstat, which is intended to provide HAE patients with a more accessible, non-invasive treatment option compared to intravenous or subcutaneous injections. This product addresses the increasing need for rapid, potent oral therapies that can be used right away during an HAE attack.

Hereditary Angioedema Therapeutics Market Leading Companies Driving Competitive Growth

Major companies operating in the hereditary angioedema therapeutics market are Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sobi AB, OctoPharma USA, HAE Pharma, Argenx SE, ImmunoGen Inc., Ionis Pharmaceuticals (for pipeline HAE therapies), PharmAthene Inc., BioMarin Pharmaceutical Inc.

Access The Complete Hereditary Angioedema Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Hereditary Angioedema Therapeutics Market Largest Region By Revenue And Market Share

North America was the largest region in the global hereditary angioedema therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Will Be The Estimated Market Size Of The Hereditary Angioedema Therapeutics Market By 2030?

The hereditary angioedema therapeutics market has exhibited substantial growth in recent years. Its valuation is projected to increase from $7.77 billion in 2025 to $9.27 billion in 2026, at a compound annual growth rate (CAGR) of 19.3%. Historically, this market’s expansion can be ascribed to factors such as limited awareness about hae, a dependency on hospital-based therapy, fewer approved therapeutic options, the reliance on intravenous administration, and low prevalence diagnosis rates.

The hereditary angioedema therapeutics market is anticipated to experience substantial growth over the next few years. It is projected to reach $19.03 billion by 2030, achieving a compound annual growth rate (CAGR) of 19.7%. This expansion during the forecast period can be attributed to the rise of recombinant C1 esterase inhibitors, the adoption of subcutaneous delivery methods, increased usage of prophylactic therapy, the broadening of specialty pharmacy channels, and greater investment in rare disease research. Significant trends for this period encompass the development of personalized therapies, an increase in orphan drug approvals, ongoing advancements in subcutaneous drug delivery, the emergence of on-demand treatment options, and the expansion of hospital and retail pharmacy networks.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

What Market Drivers Are Helping Shape The Hereditary Angioedema Therapeutics Market Expansion?

The rising healthcare expenditure is anticipated to foster the development of the hereditary angioedema therapeutics market moving forward. Healthcare expenditure signifies the cumulative amount of resources, including financial means, dedicated to healthcare products and services within a specific timeframe in a particular geographic region. Elevated healthcare spending enables increased allocation to research and development initiatives focused on unraveling the fundamental causes of hereditary angioedema and pioneering advanced therapeutic solutions. For example, in June 2025, the US-based federal agency, Centers for Medicare & Medicaid Services (CMS), indicated that the National Health Expenditure (NHE) rose by 7.5% to $4.9 trillion in 2023, which is $14,570 per person, and represented 17.6% of the Gross Domestic Product (GDP). Hospital spending experienced a 10.4% increase, reaching $1,519.7 billion in 2023, which was a faster rate compared to the 3.2% growth recorded in 2022. Thus, the escalating healthcare expenditure is stimulating the growth of the hereditary angioedema therapeutics market.

What Are The Core Segment Classifications In The Hereditary Angioedema Therapeutics Market?

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-Demand

Which Trends Are Shaping The Hereditary Angioedema Therapeutics Market Landscape?

Leading companies in the hereditary angioedema (HAE) therapeutics market are developing innovative treatments, such as oral plasma kallikrein inhibitors, to improve patient management and offer effective, on-demand options for relieving HAE attacks, thereby enhancing overall patient outcomes and quality of life. Oral plasma kallikrein inhibitors are medications taken by mouth that inhibit the enzyme plasma kallikrein, helping to control and reduce the severity of hereditary angioedema attacks. For example, in September 2024, KalVista Pharmaceuticals, a US-based biopharmaceutical company, received US Food and Drug Administration approval for its New Drug Application for Sebetralstat, aiming to provide HAE patients with a more convenient, non-invasive treatment alternative to intravenous or subcutaneous medications. This solution addresses the growing demand for rapid, effective oral treatments that can be administered instantly during an hereditary angioedema attack.

Which Companies Form The Competitive Landscape Of The Hereditary Angioedema Therapeutics Market?

Major companies operating in the hereditary angioedema therapeutics market are Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sobi AB, OctoPharma USA, HAE Pharma, Argenx SE, ImmunoGen Inc., Ionis Pharmaceuticals (for pipeline HAE therapies), PharmAthene Inc., BioMarin Pharmaceutical Inc.

Access The Complete Hereditary Angioedema Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Which Region Is The Dominant Market In The Hereditary Angioedema Therapeutics Market?

North America was the largest region in the global hereditary angioedema therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Hereditary Angioedema Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

Browse Through More Reports Similar to the Global Hereditary Angioedema Therapeutics Market 2026, By The Business Research Company

Hereditary Angioedema Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Angina Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Hereditary Angioedema Therapeutics Market During 2026–2030?

The hereditary angioedema therapeutics market size has seen rapid expansion in recent years. It is anticipated to grow from $7.77 billion in 2025 to $9.27 billion in 2026, achieving a compound annual growth rate (CAGR) of 19.3%. During the historical period, this growth was driven by factors including limited awareness about HAE, reliance on hospital-based therapy, a scarcity of approved therapeutic options, the need for intravenous administration, and low prevalence diagnosis rates.

The hereditary angioedema therapeutics market is projected to experience substantial expansion in the coming years, reaching a valuation of $19.03 billion by 2030, propelled by a compound annual growth rate (CAGR) of 19.7%. This anticipated growth during the forecast period is primarily driven by factors such as the increasing development of recombinant C1 esterase inhibitors, the widespread adoption of subcutaneous delivery methods, the escalating use of prophylactic therapies, the broadening reach of specialty pharmacy channels, and a surge in investment dedicated to rare disease research. Key trends expected over the forecast period encompass the evolution of personalized therapies, an uptick in orphan drug approvals, significant advancements in subcutaneous drug delivery, the emergence of on-demand treatment solutions, and the broadening of hospital and retail pharmacy networks.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

What Leading Drivers Are Supporting The Hereditary Angioedema Therapeutics Market Expansion?

The anticipated rise in healthcare spending is projected to propel the expansion of the hereditary angioedema therapeutics market in the future. Healthcare expenditure signifies the overall sum of resources, particularly financial ones, allocated to healthcare products and services within a defined timeframe and geographic region. Enhanced healthcare spending facilitates greater investment in research and development efforts aimed at comprehending the root causes of hereditary angioedema and devising novel treatment options. As an illustration, data from June 2025 by the US federal agency, the Centers for Medicare & Medicaid Services (CMS), indicated that the National Health Expenditure (NHE) expanded by 7.5% to reach $4.9 trillion in 2023, equating to $14,570 per individual, and represented 17.6% of the Gross Domestic Product (GDP). In 2023, hospital spending increased by 10.4% to $1,519.7 billion, surpassing the 3.2% growth observed in 2022. Consequently, the growing healthcare expenditure is serving as a catalyst for the expansion of the hereditary angioedema therapeutics market.

What Are The Key Segment Divisions In The Hereditary Angioedema Therapeutics Market Segment Structure?

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-Demand

What Trends Are Affecting The Growth Of The Hereditary Angioedema Therapeutics Market?

Leading companies within the hereditary angioedema (HAE) therapeutics market are actively creating advanced treatments, such as oral plasma kallikrein inhibitors, to improve patient care and provide effective, immediate options for managing HAE attacks, ultimately enhancing patient well-being and life quality. These oral plasma kallikrein inhibitors are medications taken by mouth that work by blocking the plasma kallikrein enzyme, aiding in the control and reduction of the intensity of hereditary angioedema episodes. For example, in September 2024, KalVista Pharmaceuticals, a US-based biopharmaceutical firm, received a New Drug Application acceptance from the US Food and Drug Administration for Sebetralstat, intending to offer HAE patients a more convenient, non-invasive treatment alternative compared to intravenous or subcutaneous drugs. This innovation addresses the increasing need for rapid, effective oral therapies that can be administered instantly during a hereditary angioedema attack.

Which Organizations Are Engaged In The Hereditary Angioedema Therapeutics Market?

Major companies operating in the hereditary angioedema therapeutics market are Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sobi AB, OctoPharma USA, HAE Pharma, Argenx SE, ImmunoGen Inc., Ionis Pharmaceuticals (for pipeline HAE therapies), PharmAthene Inc., BioMarin Pharmaceutical Inc.

Get The Full Hereditary Angioedema Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Which Region Dominates The Hereditary Angioedema Therapeutics Market By Market Share?

North America was the largest region in the global hereditary angioedema therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Hereditary Angioedema Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Hereditary Angioedema Therapeutics Market 2026, By The Business Research Company

Hereditary Angioedema Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Angina Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Hereditary Angioedema Therapeutics Market At The End Of The 2026–2030 Forecast Period?

The hereditary angioedema therapeutics market has experienced rapid expansion in its size over recent years. It is anticipated to grow from $7.77 billion in 2025 to $9.27 billion in 2026, achieving a compound annual growth rate (CAGR) of 19.3%. The market’s past growth can be ascribed to several factors, including insufficient awareness regarding hae, a dependence on hospital-centric therapy, a scarcity of approved treatment options, the predominant use of intravenous administration, and low diagnosis rates attributable to its prevalence.

The hereditary angioedema therapeutics market is anticipated to experience substantial growth in the coming years, with projections indicating it will reach $19.03 billion by 2030, demonstrating a robust compound annual growth rate (CAGR) of 19.7%. This expansion in the forecast period is primarily driven by factors such as the increasing availability of recombinant C1 esterase inhibitors, the growing adoption of subcutaneous delivery methods, an increase in the use of prophylactic therapies, the broadening reach of specialty pharmacy channels, and rising investment in rare disease research. Furthermore, significant trends expected during this period include the advancement of personalized therapies, an increase in orphan drug approvals, continued progress in subcutaneous drug delivery, the creation of on-demand treatment alternatives, and the expansion of both hospital and retail pharmacy networks.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

What Drivers Are Shaping The Future Growth Of The Hereditary Angioedema Therapeutics Market?

The rising healthcare expenditure is projected to stimulate the expansion of the hereditary angioedema therapeutics market moving forward. Healthcare expenditure signifies the total resources, including financial provisions, allocated to healthcare goods and services over a specified period within a particular geographical area. Elevated healthcare spending enables greater investment in research and development initiatives aimed at unraveling the fundamental causes of hereditary angioedema and formulating pioneering therapeutic solutions. For example, in June 2025, the Centers for Medicare & Medicaid Services (CMS), a federal agency based in the US, stated that National Health Expenditure (NHE) increased by 7.5% to $4.9 trillion in 2023, amounting to $14,570 per person, and constituted 17.6% of Gross Domestic Product (GDP). Hospital expenditures climbed by 10.4% to $1,519.7 billion in 2023, a quicker pace than the 3.2% growth recorded in 2022. Thus, the escalating healthcare expenditure is propelling the growth of the hereditary angioedema therapeutics market.

What Segment Types Make Up The Hereditary Angioedema Therapeutics Market?

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-Demand

Which Market Trends Are Creating New Opportunities In The Hereditary Angioedema Therapeutics Market?

Leading companies in the hereditary angioedema (HAE) therapeutics market are developing novel treatments, including oral plasma kallikrein inhibitors, to improve patient management and provide effective, on-demand options for alleviating HAE attacks, thereby enhancing overall patient outcomes and quality of life. Oral plasma kallikrein inhibitors are medications taken by mouth that block the plasma kallikrein enzyme, assisting in the management and reduction of hereditary angioedema attack severity. For instance, in September 2024, KalVista Pharmaceuticals, a US-based biopharmaceutical company, received US. Food and Drug Administration of New drug application for Sebetralstat, aiming to offer HAE patients a more convenient, non-invasive treatment alternative to intravenous or subcutaneous medications. This solution addresses the growing demand for fast, effective oral treatments that can be administered immediately during an hereditary angioedema attack.

Who Are The Key Players Driving Competition In The Hereditary Angioedema Therapeutics Market?

Major companies operating in the hereditary angioedema therapeutics market are Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sobi AB, OctoPharma USA, HAE Pharma, Argenx SE, ImmunoGen Inc., Ionis Pharmaceuticals (for pipeline HAE therapies), PharmAthene Inc., BioMarin Pharmaceutical Inc.

Read the full hereditary angioedema therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Which Geographic Regions Are Influencing Demand In The Hereditary Angioedema Therapeutics Market?

North America was the largest region in the global hereditary angioedema therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Hereditary Angioedema Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10810&type=smp

Browse Through More Reports Similar to the Global Hereditary Angioedema Therapeutics Market 2026, By The Business Research Company

Hereditary Angioedema Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Angina Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the hereditary angioedema therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Hereditary Angioedema Therapeutics Market in 2030?

The hereditary angioedema therapeutics market size has shown substantial growth in recent years. It is forecast to expand from $7.77 billion in 2025 to $9.27 billion in 2026, achieving a compound annual growth rate (CAGR) of 19.3%. This historical expansion can be attributed to several factors, including limited awareness about HAE, a reliance on hospital-based therapies, a scarcity of approved treatment options, the predominant use of intravenous administration, and low prevalence diagnosis rates.

The hereditary angioedema therapeutics market is anticipated to experience substantial expansion in the coming years, with its size projected to reach $19.03 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 19.7%. This growth over the forecast period is driven by factors such as the rise in recombinant C1 esterase inhibitors, the adoption of subcutaneous delivery methods, increased utilization of prophylactic therapies, the expansion of specialty pharmacy channels, and greater investment in rare disease research. Prominent trends for the forecast period encompass the development of personalized therapies, a surge in orphan drug approvals, advancements in subcutaneous drug delivery, the emergence of on-demand treatment options, and the broadening of hospital and retail pharmacy networks.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

What Drivers Are Influencing Production Trends In The Hereditary Angioedema Therapeutics Market?

Future expansion of the hereditary angioedema therapeutics market is anticipated, driven by the rising expenditure on healthcare. This expenditure represents the complete sum of resources, particularly financial, allocated to healthcare products and services over a defined timeframe in a particular region. Higher healthcare spending facilitates greater investment into research and development efforts aimed at uncovering the root causes of hereditary angioedema and creating novel treatment options. For example, data from June 2025 by the Centers for Medicare & Medicaid Services (CMS), a federal agency in the US, indicated that the National Health Expenditure (NHE) reached $4.9 trillion in 2023, growing by 7.5% or $14,570 per person, and constituting 17.6% of the Gross Domestic Product (GDP). Hospital spending specifically saw a 10.4% increase, reaching $1,519.7 billion in 2023, which surpassed the 3.2% growth observed in 2022. Consequently, the expanding healthcare expenditure is propelling the expansion of the hereditary angioedema therapeutics market.

Which Segment Groups Are Influencing The Hereditary Angioedema Therapeutics Market?

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-Demand

How Are New Market Trends Shaping The Landscape Of The Hereditary Angioedema Therapeutics Market?

Leading companies within the hereditary angioedema (HAE) therapeutics market are innovating new treatments, specifically oral plasma kallikrein inhibitors, to improve patient management and deliver effective, immediate options for relieving HAE attacks, thereby enhancing overall patient outcomes and their quality of life. These oral plasma kallikrein inhibitors are medications taken by mouth that work by inhibiting the enzyme plasma kallikrein, thus helping to manage and lessen the severity of hereditary angioedema attacks. For example, in September 2024, KalVista Pharmaceuticals, a US-based biopharmaceutical company, secured US Food and Drug Administration approval for a New Drug Application for Sebetralstat, intending to provide HAE patients with a more convenient, non-invasive treatment alternative to intravenous or subcutaneous drugs. This offering fulfills the increasing demand for quick, efficient oral treatments that can be given instantly during an hereditary angioedema attack.

Who Are The Major Companies Operating In The Hereditary Angioedema Therapeutics Market?

Major companies operating in the hereditary angioedema therapeutics market are Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sobi AB, OctoPharma USA, HAE Pharma, Argenx SE, ImmunoGen Inc., Ionis Pharmaceuticals (for pipeline HAE therapies), PharmAthene Inc., BioMarin Pharmaceutical Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Hereditary Angioedema Therapeutics Market?

North America was the largest region in the global hereditary angioedema therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Hereditary Angioedema Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10810&type=smp

Browse Through More Reports Similar to the Global Hereditary Angioedema Therapeutics Market 2026, By The Business Research Company

Hereditary Angioedema Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Angina Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the hereditary angioedema therapeutics market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Hereditary Angioedema Therapeutics Market Size?

The hereditary angioedema therapeutics market has experienced rapid growth in recent years. It is projected to expand from $6.68 billion in 2024 to $7.77 billion in 2025, reflecting a compound annual growth rate (CAGR) of 16.3%. This historic growth can be attributed to factors like improved diagnosis and awareness, increased treatment access, research and development initiatives, patient advocacy and education, and favorable regulatory approvals.

The hereditary angioedema therapeutics market is anticipated to undergo significant expansion over the next few years. Its valuation is projected to reach $15.84 billion by 2029, exhibiting a robust compound annual growth rate (CAGR) of 19.5%. This growth during the forecast period stems from advancements in targeted therapies, the broadening scope of the global market, ongoing developments in gene therapy, evolving personalized medicine trends, and increased collaboration in research and treatment efforts. Prominent trends for this period include global access initiatives, a focus on health economic outcomes research, the implementation of early intervention strategies, and the development of pediatric HAE therapeutics.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

What Core Market Drivers Are Expanding The Hereditary Angioedema Therapeutics Industry?

The increasing occurrence of hereditary angioedema is anticipated to propel the growth of the hereditary angioedema market in the foreseeable future. Hereditary angioedema (HAE) is a rare genetic disorder marked by recurrent episodes of severe swelling affecting the skin and mucous membranes. This swelling is caused by an excess fluid build-up (EDEMA) and can manifest anywhere in the body, including the hands and feet, face, intestines, and airways. For instance, in June 2022, according to Rare Disease Advisor, an online resource for healthcare professionals, approximately 1 in every 50,000 persons globally suffer from hereditary angioedema, with prevalence estimates ranging from 1:10,000 to 1:150,000. HAE episodes lead to 15,000 to 30,000 emergency room visits each year in the US. Furthermore, 5.8% of HAE cases had an average time to diagnosis of 0 to 6 months, whereas 5.8% had an average time to diagnosis of over 10 years. Therefore, the rising prevalence of hereditary angioedema is a key factor driving the expansion of the hereditary angioedema market.

What Segment Insights Are Highlighted In The Hereditary Angioedema Therapeutics Market Report?

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-demand

Subsegments:

1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant

2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant

3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab

4) By Other Drug Classes: Emerging Therapies

Which Notable Trends Are Transforming The Hereditary Angioedema Therapeutics Market Outlook?

A significant trend gaining traction in the hereditary angioedema therapeutics market involves product innovations. Major companies within this market are actively developing pioneering products like ligand-conjugated (LICA) investigational antisense medicine and gene therapy to secure their market standing. For instance, in March 2023, Intellia Therapeutics, a US-based clinical-stage biotechnology company, unveiled NTLA-2002, an Investigational New Drug (IND), which received approval from the United States Food and Drug Administration for the treatment of hereditary angioedema. This approval permits the inclusion of the US in the worldwide Phase 2 part of the company’s ongoing Phase 1/2 trial. Following a single therapeutic dose, the inactivation of the target gene, kallikrein B1 (KLKB1), is intended to permanently decrease plasma kallikrein protein activity and prevent HAE attacks. NTLA-2002 is considered a candidate for in vivo genome editing.

Which Firms Are Driving Innovation Within The Hereditary Angioedema Therapeutics Market?

Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

What Regional Trends Are Shaping Growth In The Hereditary Angioedema Therapeutics Market?

North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=10810&type=smp

Browse Through More Reports Similar to the Global Hereditary Angioedema Therapeutics Market 2025, By The Business Research Company

Cold Pain Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cold-pain-therapy-global-market-report

Physical Therapy Software Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/physical-therapy-software-global-market-report

Vitamin D Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vitamin-d-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Hereditary Angioedema Therapeutics Industry Compare Between 2025 And 2029?

The hereditary angioedema therapeutics market has seen rapid expansion in recent years. Its valuation is anticipated to rise from $6.68 billion in 2024 to $7.77 billion in 2025, reflecting a compound annual growth rate (CAGR) of 16.3%. The market’s past growth can be ascribed to improved diagnosis and public awareness, expanded access to treatments, various research and development initiatives, patient advocacy and educational efforts, and successful regulatory approvals.

The hereditary angioedema therapeutics market is projected to experience substantial expansion over the upcoming years. This market is set to reach $15.84 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 19.5%. The anticipated growth during this period stems from factors such as advancements in targeted therapies, expansion into global markets, breakthroughs in gene therapy, the increasing adoption of personalized medicine, and enhanced collaboration in both research and treatment efforts. Key trends identified for the forecast period encompass global access initiatives, extensive health economic outcomes research, the implementation of early intervention strategies, and the development of therapeutics specifically for pediatric HAE.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

Which Factors And Drivers Are Influencing The Hereditary Angioedema Therapeutics Market In 2025?

The increasing occurrence of hereditary angioedema is anticipated to drive the expansion of the hereditary angioedema market in the foreseeable future. Hereditary angioedema, often abbreviated as HAE, is an uncommon inherited condition marked by repeated occurrences of intense swelling affecting the skin and internal lining tissues. This swelling results from an accumulation of surplus fluid, known as EDEMA, and has the potential to manifest in any part of the body, such as the hands, feet, face, digestive system, and respiratory passages. As an illustration, in June 2022, data from Rare Disease Advisor, an online platform for healthcare professionals, indicated that globally, 1 in every 50,000 persons suffer from hereditary angioedema, with prevalence estimates spanning from 1:10,000 to 1:150,000. Annually in the US, HAE episodes lead to 15,000 to 30,000 emergency room visits. A segment of HAE cases, specifically 5.8%, recorded an average diagnostic period of 0 to 6 months, while another 5.8% experienced an average diagnosis time exceeding over 10 years. Consequently, the growing incidence of hereditary angioedema is a key factor propelling the expansion of the hereditary angioedema market.

What Are The Key Segments In The Hereditary Angioedema Therapeutics Market?

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-demand

Subsegments:

1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant

2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant

3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab

4) By Other Drug Classes: Emerging Therapies

What Trends Are Expected To Drive The Hereditary Angioedema Therapeutics Market?

Product innovations represent a significant and growing trend within the hereditary angioedema therapeutics market. Leading companies in the hereditary angioedema therapeutics market are developing cutting-edge products, such as ligand-conjugated (LICA) investigational antisense medicine and gene therapy, to solidify their market standing. For instance, in March 2023, Intellia Therapeutics, a clinical-stage biotechnology firm located in the US, introduced an Investigational New Drug (IND) called NTLA-2002. The United States Food and Drug Administration had approved this drug for treating hereditary angioedema. This development enables the company’s ongoing Phase 1/2 trial to extend its reach to encompass the US within the worldwide Phase 2 portion. Following a single therapeutic administration, the inactivation of the target gene, kallikrein B1 (KLKB1), is expected to result in a permanent reduction of plasma kallikrein protein activity, thereby preventing HAE attacks. NTLA-2002 is considered a candidate for in vivo genome editing.

Which Industry Leaders Are Driving Innovation Across The Hereditary Angioedema Therapeutics Market?

Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Hereditary Angioedema Therapeutics Market?

North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Hereditary Angioedema Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=10810&type=smp

Browse Through More Reports Similar to the Global Hereditary Angioedema Therapeutics Market 2025, By The Business Research Company

Cold Pain Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cold-pain-therapy-global-market-report

Physical Therapy Software Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/physical-therapy-software-global-market-report

Vitamin D Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vitamin-d-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Hereditary Angioedema Therapeutics Sector?

The market size for hereditary angioedema therapeutics has seen a swift expansion in the most recent years. The projected growth will take it from $6.68 billion in 2024 to $7.77 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 16.3%. Factors contributing to the growth observed in the historical period include enhanced diagnosis and awareness, increased access to treatment, research and development efforts, educating and advocating for patients, as well as regulatory approvals.

The market for therapeutics for hereditary angioedema is projected to experience swift expansion in the coming years, reaching an estimated “$15.84 billion by 2029, translating to a compound annual growth rate (CAGR) of 19.5%.” The anticipated market growth during the forecast period could be due to progress in targeted treatments, global market enlargement, advancements in gene therapy, personalized medicine tendencies, and partnerships in therapeutic research. Dominant trends expected during this forecast include initiatives for global accessibility, research into health economic outcomes, strategies for early intervention, and therapeutics for pediatric HAE.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

What Forces Are Driving The Growth Of The Hereditary Angioedema Therapeutics Market?

The growth of the hereditary angioedema market is projected to be catalyzed by the increasing occurrence of the said disorder. Hereditary angioedema (HAE) is an uncommon genetic condition marked by recurrent incidents of severe swelling in the skin and mucous membranes. This swelling, brought about by the accumulation of excessive fluid or edema, can emerge in various parts of the body – hands, feet, face, intestines, and even airways. For example, Rare Disease Advisor, a global health care professional resource provider, revealed in June 2022 that there is 1 HAE patient for every 50,000 individuals universally, with the number of potential cases fluctuating from 1:10,000 to 1:150,000. Each year in the US, HAE episodes lead to between 15,000 to 30,000 visits to the emergency room. The time taken for diagnosing HAE differs, with 5.8% of cases taking anywhere from 0 to 6 months for a diagnosis, and another 5.8% taking over 10 years. Hence, it’s evident that the escalating prevalence of HAE is fueling the upsurge in the hereditary angioedema market.

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-demand

Subsegments:

1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant

2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant

3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab

4) By Other Drug Classes: Emerging Therapies

How Are Key Trends Driving Expansion In The Hereditary Angioedema Therapeutics Industry?

A significant trend emerging in the hereditary angioedema therapeutics market is the emphasis on product innovation. Key players in the market are focusing on the development of novel products such as Ligand-Conjugated (LICA) experimental antisense medicine and gene therapy to maintain their market position. For example, Intellia Therapeutics, a US-based biotechnology firm in its clinical stages, introduced an Investigational New Drug (IND) NTLA-2002, in March 2023. The drug, approved by the United States Food and Drug Administration, treats hereditary angioedema and facilitates the inclusion of the US in the global phase 2 trial portion of the ongoing Phase 1/2 trial. The therapy, after a single dose, inactivates the kallikrein B1 (KLKB1) gene target permanently, thereby reducing plasma kallikrein protein activity and preventing HAE attacks. Hence, NTLA-2002 is a potential candidate for in vivo genome editing.

Which Companies Currently Dominate The Competitive Landscape In The Hereditary Angioedema Therapeutics Industry?

Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Which Geographic Regions Are Driving Demand In The Hereditary Angioedema Therapeutics Market?

North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10810&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model